Alprostadil vs PT-141 (Bremelanotide)
A side-by-side research comparison of Alprostadil and PT-141 (Bremelanotide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Alprostadil | PT-141 (Bremelanotide) |
|---|---|---|
| Full name | Alprostadil (Prostaglandin E1) | Bremelanotide (PT-141 / Vyleesi) |
| Category | Sexual Health | Sexual Health |
| Status | FDA-approved drug (prescription) | FDA Approved |
| Mechanism | Alprostadil activates prostaglandin receptors that raise intracellular cAMP in cavernosal smooth muscle, causing vasodilation and increased blood inflow to produce an erection regardless of nerve signaling or arousal. | MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms. |
| Molecular weight | 354.5 Da | 1,025 Da |
| Half-life | Very short (minutes, locally metabolized) | 2.7 hours |
| Bioavailability | Intracavernosal injection or intraurethral suppository | High (SubQ) |
| Typical dose | Provider-titrated per response | 1.75 mg |
| Frequency | As needed before activity | As needed, ~45 min before activity |
| Route | Intracavernosal injection or urethral pellet | Subcutaneous injection |
Alprostadil reported benefits
- Effective for erectile dysfunction
- Works independent of arousal
- Rapid onset
- Useful when oral PDE5 inhibitors fail
PT-141 (Bremelanotide) reported benefits
- Increased sexual desire
- Central arousal mechanism
- Works both sexes (research)
- Non-vascular
- Rapid onset
Related comparisons
Research and educational reference only. Not medical advice.